Phase 3 RCT in 500 patients with pretreated advanced solid tumours: ultra-low-dose nivolumab (20 mg) improved median OS versus docetaxel or paclitaxel (5.88 vs 4.70 months; HR 0.80), with similar PFS and fewer grade 3+ treatment-related adverse events (42.5% vs 60.8%).
RCTn = 500 patients
Noronha et al. Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)